Immuneering Corporation (IMRX), a biopharmaceutical company based in Massachusetts, announced promising developments from its Phase 2a trial of IMM-1-104, in conjunction with modified FOLFIRINOX (mFFX), for initial treatment of pancreatic cancer. Alongside, the company shared a broader corporate update.
As of January 6, 2025, six evaluable participants were included in this study, leading to three patients experiencing partial responses, one pending confirmation. This translates to an overall response rate (ORR) of 50%, with four patients still undergoing treatment. Historically, the ORR for FOLFIRINOX alone is 32%.
The IMM-1-104 and mFFX combination was predominantly well-tolerated. Immuneering is also assessing the 320 mg once-daily dose of IMM-1-104 alongside the modified FOLFIRINOX regimen.
Furthermore, following the January 7, 2025 report on its ongoing Phase 2a trials, the company successfully generated $13.7 million in net proceeds via its At-the-Market (ATM) facility.
Looking ahead, Immuneering plans to disclose additional Phase 2a results for IMM-1-104 in the second quarter of 2025. The company is also preparing to initiate Phase 2a trials, combining IMM-1-104 with a BRAF inhibitor and a checkpoint inhibitor, within the same year.
On Monday, IMRX shares closed at $2.01, marking a decrease of 2.8985%. Following trading hours on the Nasdaq Global Select Market, the shares further declined, closing at $2, down by 0.4975%.
